Starpharma presents at ASX Small to Mid Caps conference, Hong Kong
Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) is one of 20 Australian companies, and one of only two Biotechs, selected to present at the third annual ASX Small to Mid Caps conference in Hong Kong. The ASX Hong Kong conference is part of a series of international investor events designed to showcase emerging Australian small and mid-cap listed companies to investors in Asia, Europe and the US.
Starpharma Expands Lilly Partnership
Starpharma today announced the signing of a collaborative research agreement with leading US pharmaceutical corporation Eli Lilly and Company.
The new agreement relates to a co-development program for one of Starpharma’s dendrimer-drug conjugates.
Starpharma annual report and full year financial results
Starpharma today released its annual report and financial results for the year ended 30 June 2010.
Cash reserves of $22.8 million are a result of prudent management of cash, successful capital raising and continuing partnering revenues, and interest received throughout the year.
The 6th Bioshares 2010 Biotech Summit
Abstract: While much has been communicated about Starpharma's Vivagel product and its application as a microbicidal condom coating, the company was asked to present on the rapidly strengthening interest in the use of the company's dendrimers for the application of drug delivery.
Download: Bioshares Issue 369 ( pdf file, 26kb)